I leave it for more science educated posters, but my quick take away:
- it was 10 years ago - in Korea (!!!) - Limitations of this study include weak statistical power due to the small patient group and the low event rate [The 12.6% was a yearly event rate since the study - follow-up - was 12-month for each patient]
What are the chances that the rate in R-IT is actually much larger than 5.9%?
We have a good chance. The extra 1,000 patients allow (but does not predict) lower (5.2%) rate than 5.9%. pre-SPA 5.9% means, they expected more.
- - - - - centurycom #76967
If you mean "1,050 or 1,100": these were just for example if you mean "more than 967": The combination of the many CV events which have been adjudicated together with the CV events pending adjudicated. Adjudication is starting after occurrence.
My quick take ...this study measured the "on treatment " effect of the statins on ALL the trial participants . There was no "placebo " group. These patients underwent PCI and were started on Satin therapy before discharge .
This group was also very high risk Before discharge and at start of therapy 98.6 % now with drug eluting stents 87.3 % on ACE /ARD HsCRP over 4 at start of therapy. etc
My read is that these patients were NOT on statins before starting the trial where as in RI I believe all were . Just my quick take Kiwi